Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.

The oncologist - 1 May 2018

Perets Ruth, Greenberg Orli, Shentzer Talia, Semenisty Valeria, Epelbaum Ron, Bick Tova, Sarji Shada, Ben-Izhak Ofer, Sabo Edmond, Hershkovitz Dov

Abstract excerpt

BACKGROUND: Many new pancreatic cancer treatment combinations have been discovered in recent years, yet the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains grim. The advent of new treatments highlights the need for better monitoring tools for treatment response, to allow a timely switch between different therapeutic regimens. Circulating tumor DNA (ctDNA) is a tool for cancer detection and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Circulating Tumor DNA

Share to Mutation

Share to Pancreatic Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 29371474
DOI: 10.1634/theoncologist.2017-0467
PMCID: PMC5947453

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.PMID 29371474Read ↗

Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.Semantic proximity Read ↗

Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancerSemantic proximity Read ↗

Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging.Semantic proximity Read ↗

Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.Semantic proximity Read ↗

Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.Semantic proximity Read ↗

Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic CancerSemantic proximity Read ↗

Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.Semantic proximity Read ↗

Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients.Semantic proximity Read ↗

Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicenter Cohort Study.Semantic proximity Read ↗

Evaluation of circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasisSemantic proximity Read ↗

Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.